HAE Stock: Haemonetics Corporation Stock Price, Analysis & Insights
Get live hae stock price $67.11, comprehensive Haemonetics Corporation stock analysis, charts, news, and expert forecast. Real-time hae stock data and investment insights.
Loading chart...
Company Overview
Haemonetics Corporation, a healthcare company, provides medical products and solutions. It operates through three segments: Plasma, Blood Center, and Hospital. The company offers automated plasma collection devices, related disposables, and software, including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG, ClotPro, and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions; and Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. It markets and sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.
Company Information
- CEO
- Christopher A. Simon
- Sector
- Healthcare
- Industry
- Medical - Instruments & Supplies
- Employees
- 3657
Contact Information
- Website
- https://www.haemonetics.com
- Address
- 125 Summer Street
- Country
- US
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Growth-oriented company with premium valuation (P/E: 20.5)
✓ Lower volatility stock (Beta: 0.36) may provide portfolio stability
Business Model & Strategy
Haemonetics Corporation operates in the Medical - Instruments & Supplies industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Christopher A. Simon, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Medical - Instruments & Supplies model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Haemonetics Corporation competes in the Medical - Instruments & Supplies within the broader Healthcare. With 3.2 billion in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the New York Stock Exchange, Haemonetics Corporation provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Haemonetics Corporation should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Haemonetics Corporation shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Haemonetics Corporation
- ⚠Investors should consider how Haemonetics Corporation fits within their overall portfolio allocation
Market Cap
3.23B
P/E Ratio
20.52
Beta
0.36
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 3.23B market capitalization
- Trading Volume: 4.15M shares traded today
- Price Range: 52-week range of $47.32 - $94.99
- Exchange: Listed on New York Stock Exchange
Financial Metrics
Market Analysis for Haemonetics Corporation
Haemonetics Corporation (HAE) operates in the Medical - Instruments & Supplies industry within the Healthcare sector. With a current market capitalization of 3.23B, the company represents a significant player in its market. The stock is currently trading at $67.11 with a positivedaily change of 32.31%.
The company's 3657 employee base and presence on the New York Stock Exchangeexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of 20.52, beta of 0.36, and 52-week price range from $47.32 to $94.99when evaluating investment opportunities.
Why Invest in Haemonetics Corporation?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (New York Stock Exchange)
- • Experienced leadership under Christopher A. Simon
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.